RareStone’s narcolepsy therapy receives approval in China

The Chinese NMPA has granted approval for RareStone Group’s pitolisant to treat cataplexy in adult narcolepsy patients.

Jul 5, 2023 - 20:00

RareStone’s narcolepsy therapy receives approval in China

The Chinese NMPA has granted approval for RareStone Group’s pitolisant to treat cataplexy in adult narcolepsy patients.

Read the original article

Tags:

Previous Article

NHS to provide vision-saving drug to premature babies

Labcorp forms spin-off of Fortrea

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment

STAT+: Pharmalittle: German regulator eyes Ozempic expo...

Nov 15, 2023

Opinion: Lessons from Ukraine on protecting mental health during conflict

Opinion: Lessons from Ukraine on protecting mental heal...

Sep 22, 2023

Watch: What is in utero gene editing?

Watch: What is in utero gene editing?

Feb 21, 2024